Pharming's Joenja Revenue Jumps 34% in Q1, Secures Japan Approval, Resubmits FDA sNDA for Pediatric Expansion
PHAR sits 98% above its 52-week low of $8.395 on light trading volume (0.2× avg).
Summary
Pharming Group reported mixed first-quarter 2026 financial results, with total revenues decreasing 8% year-over-year to US$72.4 million, primarily due to anticipated declines in RUCONEST revenue. However, Joenja revenue surged 34% to US$14.1 million, driven by strong patient uptake in the U.S. and international markets. The company reaffirmed its full-year 2026 revenue guidance of US$405 - US$425 million and generated positive net cash flow from operations. Significant regulatory progress was also announced, including Joenja's approval in Japan for APDS patients and the resubmission of a pediatric sNDA to the FDA for the highest doses, with plans for an additional sNDA this summer. While the positive CHMP opinion for Joenja in Europe was reiterated, having been previously disclosed in a March 27, 2026 filing, the Japan approval and FDA resubmission represent new and material catalysts. This report provides a comprehensive update on the company's financial performance and key product pipeline, highlighting Joenja as a critical growth driver. Traders will be watching for further updates on the FDA's review of the sNDA and the commercial rollout of Joenja in new markets.
At the time of this announcement, PHAR was trading at $16.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $8.39 to $21.34. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.